Neurofilament light-chain (NfL) and 18 kDa translocator protein in early psychosis and its putative high-risk
Evidence of elevated peripheral Neurofilament light-chain (NfL) as a biomarker of neuronal injury can be utilized to reveal nonspecific axonal damage, which could reflect altered neuroimmune function. To date, only a few studies have investigated NfL as a fluid biomarker in schizophrenia primarily,...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-05-01
|
| Series: | Brain, Behavior, & Immunity - Health |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666354624000206 |
| _version_ | 1797221732011999232 |
|---|---|
| author | Kankana Nisha Aji Giulia Cisbani Ana Weidenauer Alex Koppel Sina Hafizi Tania Da Silva Michael Kiang Pablo M. Rusjan Richard P. Bazinet Romina Mizrahi |
| author_facet | Kankana Nisha Aji Giulia Cisbani Ana Weidenauer Alex Koppel Sina Hafizi Tania Da Silva Michael Kiang Pablo M. Rusjan Richard P. Bazinet Romina Mizrahi |
| author_sort | Kankana Nisha Aji |
| collection | DOAJ |
| description | Evidence of elevated peripheral Neurofilament light-chain (NfL) as a biomarker of neuronal injury can be utilized to reveal nonspecific axonal damage, which could reflect altered neuroimmune function. To date, only a few studies have investigated NfL as a fluid biomarker in schizophrenia primarily, though none in its putative prodrome (Clinical High-Risk, CHR) or in untreated first-episode psychosis (FEP). Further, it is unknown whether peripheral NfL is associated with 18 kDa translocator protein (TSPO), a validated neuroimmune marker. In this secondary study, we investigated for the first time (1) serum NfL in early stages of psychosis including CHR and FEP as compared to healthy controls, and (2) examined its association with brain TSPO, using [18F]FEPPA positron emission tomography (PET). Further, in the exploratory analyses, we aimed to assess associations between serum NfL and symptom severity in patient group and cognitive impairment in the combined cohort. A large cohort of 84 participants including 27 FEP (24 antipsychotic-naive), 41 CHR (34 antipsychotic-naive) and 16 healthy controls underwent structural brain MRI and [18F]FEPPA PET scan and their blood samples were obtained and assessed for serum NfL concentrations. We found no significant differences in serum NfL levels across clinical groups, controlling for age. We also found no significant association between NfL levels and brain TSPO in the entire cohort. We observed a negative association between serum NfL and negative symptom severity in CHR. Our findings suggest that neither active neuroaxonal deterioration as measured with NfL nor associated neuroimmune activation (TSPO) is clearly identifiable in an early mostly untreated psychosis sample including its putative high-risk. |
| first_indexed | 2024-04-24T13:10:06Z |
| format | Article |
| id | doaj.art-d8cf2493506d4bcab2dd2e9e16fc6c67 |
| institution | Directory Open Access Journal |
| issn | 2666-3546 |
| language | English |
| last_indexed | 2024-04-24T13:10:06Z |
| publishDate | 2024-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Brain, Behavior, & Immunity - Health |
| spelling | doaj.art-d8cf2493506d4bcab2dd2e9e16fc6c672024-04-05T04:41:39ZengElsevierBrain, Behavior, & Immunity - Health2666-35462024-05-0137100742Neurofilament light-chain (NfL) and 18 kDa translocator protein in early psychosis and its putative high-riskKankana Nisha Aji0Giulia Cisbani1Ana Weidenauer2Alex Koppel3Sina Hafizi4Tania Da Silva5Michael Kiang6Pablo M. Rusjan7Richard P. Bazinet8Romina Mizrahi9Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada; Douglas Research Centre, Clinical and Translational Sciences Lab, Montreal, Quebec, Canada; Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, CanadaDepartment of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, CanadaDivision of General Psychiatry, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, AustriaDepartment of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada; Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, CanadaResearch Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, CanadaResearch Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, CanadaResearch Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, CanadaDouglas Research Centre, Clinical and Translational Sciences Lab, Montreal, Quebec, Canada; Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, McGill University, Montreal, Quebec, CanadaDepartment of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Corresponding author. Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, M5S 1A8, Canada.Douglas Research Centre, Clinical and Translational Sciences Lab, Montreal, Quebec, Canada; Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, McGill University, Montreal, Quebec, Canada; Corresponding author. Department of Psychiatry, McGill University, Clinical and Translational Sciences (CaTS) Lab, Douglas Research Centre, Montreal, Quebec, H4H 1R3, Canada.Evidence of elevated peripheral Neurofilament light-chain (NfL) as a biomarker of neuronal injury can be utilized to reveal nonspecific axonal damage, which could reflect altered neuroimmune function. To date, only a few studies have investigated NfL as a fluid biomarker in schizophrenia primarily, though none in its putative prodrome (Clinical High-Risk, CHR) or in untreated first-episode psychosis (FEP). Further, it is unknown whether peripheral NfL is associated with 18 kDa translocator protein (TSPO), a validated neuroimmune marker. In this secondary study, we investigated for the first time (1) serum NfL in early stages of psychosis including CHR and FEP as compared to healthy controls, and (2) examined its association with brain TSPO, using [18F]FEPPA positron emission tomography (PET). Further, in the exploratory analyses, we aimed to assess associations between serum NfL and symptom severity in patient group and cognitive impairment in the combined cohort. A large cohort of 84 participants including 27 FEP (24 antipsychotic-naive), 41 CHR (34 antipsychotic-naive) and 16 healthy controls underwent structural brain MRI and [18F]FEPPA PET scan and their blood samples were obtained and assessed for serum NfL concentrations. We found no significant differences in serum NfL levels across clinical groups, controlling for age. We also found no significant association between NfL levels and brain TSPO in the entire cohort. We observed a negative association between serum NfL and negative symptom severity in CHR. Our findings suggest that neither active neuroaxonal deterioration as measured with NfL nor associated neuroimmune activation (TSPO) is clearly identifiable in an early mostly untreated psychosis sample including its putative high-risk.http://www.sciencedirect.com/science/article/pii/S2666354624000206First-episode psychosisClinical high-riskNeurofilament light-chainNeuroinflammationPETTSPO |
| spellingShingle | Kankana Nisha Aji Giulia Cisbani Ana Weidenauer Alex Koppel Sina Hafizi Tania Da Silva Michael Kiang Pablo M. Rusjan Richard P. Bazinet Romina Mizrahi Neurofilament light-chain (NfL) and 18 kDa translocator protein in early psychosis and its putative high-risk Brain, Behavior, & Immunity - Health First-episode psychosis Clinical high-risk Neurofilament light-chain Neuroinflammation PET TSPO |
| title | Neurofilament light-chain (NfL) and 18 kDa translocator protein in early psychosis and its putative high-risk |
| title_full | Neurofilament light-chain (NfL) and 18 kDa translocator protein in early psychosis and its putative high-risk |
| title_fullStr | Neurofilament light-chain (NfL) and 18 kDa translocator protein in early psychosis and its putative high-risk |
| title_full_unstemmed | Neurofilament light-chain (NfL) and 18 kDa translocator protein in early psychosis and its putative high-risk |
| title_short | Neurofilament light-chain (NfL) and 18 kDa translocator protein in early psychosis and its putative high-risk |
| title_sort | neurofilament light chain nfl and 18 kda translocator protein in early psychosis and its putative high risk |
| topic | First-episode psychosis Clinical high-risk Neurofilament light-chain Neuroinflammation PET TSPO |
| url | http://www.sciencedirect.com/science/article/pii/S2666354624000206 |
| work_keys_str_mv | AT kankananishaaji neurofilamentlightchainnfland18kdatranslocatorproteininearlypsychosisanditsputativehighrisk AT giuliacisbani neurofilamentlightchainnfland18kdatranslocatorproteininearlypsychosisanditsputativehighrisk AT anaweidenauer neurofilamentlightchainnfland18kdatranslocatorproteininearlypsychosisanditsputativehighrisk AT alexkoppel neurofilamentlightchainnfland18kdatranslocatorproteininearlypsychosisanditsputativehighrisk AT sinahafizi neurofilamentlightchainnfland18kdatranslocatorproteininearlypsychosisanditsputativehighrisk AT taniadasilva neurofilamentlightchainnfland18kdatranslocatorproteininearlypsychosisanditsputativehighrisk AT michaelkiang neurofilamentlightchainnfland18kdatranslocatorproteininearlypsychosisanditsputativehighrisk AT pablomrusjan neurofilamentlightchainnfland18kdatranslocatorproteininearlypsychosisanditsputativehighrisk AT richardpbazinet neurofilamentlightchainnfland18kdatranslocatorproteininearlypsychosisanditsputativehighrisk AT rominamizrahi neurofilamentlightchainnfland18kdatranslocatorproteininearlypsychosisanditsputativehighrisk |